Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for QNRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2009. Start Trial.
Date Value
June 30, 2026 3.933M
March 31, 2026 8.773M
December 31, 2025 13.12M
September 30, 2025 -1.215M
June 30, 2025 2.551M
March 31, 2025 5.926M
December 31, 2024 9.205M
September 30, 2024 5.442M
June 30, 2024 7.478M
March 31, 2024 9.126M
December 31, 2023 5.664M
September 30, 2023 7.414M
June 30, 2023 9.072M
March 31, 2023 10.91M
December 31, 2022 7.407M
September 30, 2022 9.168M
June 30, 2022 -3.168M
March 31, 2022 -0.7294M
December 31, 2021 0.657M
September 30, 2021 -16.25M
June 30, 2021 1.756M
March 31, 2021 -10.51M
December 31, 2020 -6.607M
September 30, 2020 5.790M
June 30, 2020 6.296M
Date Value
March 31, 2020 6.180M
December 31, 2019 4.296M
September 30, 2019 5.313M
June 30, 2019 6.143M
March 31, 2019 6.058M
December 31, 2018 3.726M
September 30, 2018 4.506M
June 30, 2018 6.042M
March 31, 2018 7.739M
December 31, 2017 5.430M
September 30, 2017 5.902M
June 30, 2017 4.282M
March 31, 2017 4.827M
December 31, 2016 7.402M
September 30, 2016 8.503M
June 30, 2016 3.338M
March 31, 2016 3.972M
December 31, 2015 2.699M
September 30, 2015 3.476M
June 30, 2015 4.221M
March 31, 2015 2.873M
December 31, 2014 3.330M
September 30, 2014 3.906M
June 30, 2014 4.573M
March 31, 2014 0.7366M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics